Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism

Expert Opin Investig Drugs. 2003 Aug;12(8):1413-21. doi: 10.1517/13543784.12.8.1413.


Cinacalcet HCl (AMG 073) is an investigational oral calcimimetic drug currently being evaluated for the treatment of primary and secondary hyperparathyroidism (HPT). Calcimimetics bind to the calcium-sensing receptors of the parathyroid glands and lower the sensitivity for receptor activation by extracellular calcium, thereby diminishing parathyroid hormone release. Cinacalcet HCl has demonstrated efficacy in controlling the hypercalcaemia of severe primary HPT and in reducing parathyroid hormone levels in patients with secondary HPT. Asymptomatic dose-dependent hypocalcaemia has occurred in some clinical trials. This drug has a favourable pharmacokinetic profile compared to its precursors and will prove useful as an additional/alternative agent in patients with primary and secondary HPT.

Publication types

  • Review

MeSH terms

  • Cinacalcet
  • Humans
  • Hypercalcemia / etiology
  • Hyperparathyroidism / complications
  • Hyperparathyroidism / drug therapy*
  • Hyperparathyroidism / metabolism
  • Hyperparathyroidism, Secondary / drug therapy
  • Hyperparathyroidism, Secondary / etiology
  • Kidney Failure, Chronic / complications
  • Naphthalenes / administration & dosage
  • Naphthalenes / therapeutic use*
  • Parathyroid Hormone / biosynthesis
  • Randomized Controlled Trials as Topic
  • Receptors, Calcium-Sensing
  • Receptors, Cell Surface / metabolism


  • Naphthalenes
  • Parathyroid Hormone
  • Receptors, Calcium-Sensing
  • Receptors, Cell Surface
  • Cinacalcet